These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy. Piu C; Ibba G; Bertoli D; Capra R; Uleri E; Serra C; Imberti L; Dolei A J Neurovirol; 2020 Feb; 26(1):133-137. PubMed ID: 31468472 [TBL] [Abstract][Full Text] [Related]
9. Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation. Iannetta M; Zingaropoli MA; Bellizzi A; Morreale M; Pontecorvo S; D'Abramo A; Oliva A; Anzivino E; Lo Menzo S; D'Agostino C; Mastroianni CM; Millefiorini E; Pietropaolo V; Francia A; Vullo V; Ciardi MR PLoS One; 2016; 11(8):e0160277. PubMed ID: 27486658 [TBL] [Abstract][Full Text] [Related]
10. Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature. Zhang Y; Wright C; Flores A J Med Case Rep; 2018 Jul; 12(1):187. PubMed ID: 29960601 [TBL] [Abstract][Full Text] [Related]
12. MiR-126: a novel route for natalizumab action? Meira M; Sievers C; Hoffmann F; Derfuss T; Kuhle J; Kappos L; Lindberg RL Mult Scler; 2014 Sep; 20(10):1363-70. PubMed ID: 24598267 [TBL] [Abstract][Full Text] [Related]
13. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients. Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276 [TBL] [Abstract][Full Text] [Related]
14. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984 [TBL] [Abstract][Full Text] [Related]
15. JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab. Uleri E; Ibba G; Piu C; Caocci M; Leoni S; Arru G; Serra C; Sechi G; Dolei A J Neurovirol; 2017 Apr; 23(2):226-238. PubMed ID: 27812788 [TBL] [Abstract][Full Text] [Related]
16. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Major EO; Yousry TA; Clifford DB Lancet Neurol; 2018 May; 17(5):467-480. PubMed ID: 29656742 [TBL] [Abstract][Full Text] [Related]
17. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence. Bacchetta F; Mathias A; Schluep M; Du Pasquier R Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319 [TBL] [Abstract][Full Text] [Related]
18. Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathy. Kinner M; Prehn C; Schneider R; Schroeder C; Kolb E; Gold R; Hoepner R; Chan A Eur J Neurol; 2021 Mar; 28(3):921-927. PubMed ID: 33085811 [TBL] [Abstract][Full Text] [Related]
19. Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis? Krämer J; Tenberge JG; Kleiter I; Gaissmaier W; Ruck T; Heesen C; Meuth SG PLoS One; 2017; 12(4):e0174858. PubMed ID: 28406921 [TBL] [Abstract][Full Text] [Related]
20. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]